Mission Statement, Vision, & Core Values (2026) of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

From its roots as a subsidiary of China Resources Group to its market identity under ticker 000999.SZ, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. channels a 5% R&D reinvestment into product innovation, operates multiple GMP-certified production facilities, integrates traditional Chinese medicine with modern pharmaceuticals, and maintains a vast urban-and-rural multi-channel distribution network-setting the stage for an inside look at how its mission to 'care for public health and create a better life,' its vision to lead high-quality development, and core values of integrity, performance, people, partnership, innovation and sustainability guide strategy and partnerships at home and abroad.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ) - Intro

• Core business lines: TCM finished products, OTC consumer health, prescription modern medicines, and API supply.
• Corporate lineage: Subsidiary of China Resources Group, leveraging state-backed distribution and capital access.
• Geographic reach: Nationwide coverage across urban and rural markets in China with growing export channels.

• Manufacturing: Multiple production sites certified to national and international GMP standards; the company reports a network of primary production bases covering TCM and chemical drug manufacturing.
• Quality systems: Implementation of ISO and GMP-compliant quality management systems across core plants to support domestic and export market approvals.

• R&D intensity: CR Sanjiu invests approximately 5% of annual revenue into R&D to support formulation upgrades, clinical development, and quality improvement. For FY2023 this equated to roughly RMB 625 million (based on reported revenue ~RMB 12.5 billion).
• R&D focus areas: Modernization of classic TCM formulas, new dosage forms, bioequivalence studies, and life-cycle management of legacy products.

• Multi-channel strategy: Direct sales teams for institutional accounts, partnerships with wholesalers and distributors, e-commerce and official online stores, plus collaboration with pharmacy chains and hospital channels.
• Network scale: Coverage across all Chinese provinces and municipalities, supported by regional sales offices and logistic hubs to serve both urban hospitals and rural retail pharmacies.

• Global ties: Strategic co-development and licensing collaborations with selected global pharmaceutical partners to access overseas regulatory channels and expand export portfolios.
• Market approach: Gradual export of finished TCM products and modern formulations, with priority on Asia-Pacific and Belt-and-Road partner markets.

• Mission: To safeguard public health by integrating traditional Chinese medicine wisdom with modern pharmaceutical science, delivering safe, effective and accessible healthcare products.
• Vision: To be the trusted leader in TCM modernization and a competitive global pharmaceutical enterprise, expanding value for patients, partners and stakeholders.
• Core values: Patient-first quality, scientific integrity, innovation-driven development, collaborative partnerships, and social responsibility.

• Corporate governance: Listed entity reporting under Shenzhen Stock Exchange rules (000999.SZ) with board oversight aligned to state-shareholder expectations and minority investor protections.
• Investor engagement: Regular disclosures, annual reports and investor communications; see further context here: Exploring China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ) - Overview

• Mission: 'Care for public health and create a better life' - customer-centric delivery of safe, effective pharmaceutical products and healthcare services.
• Vision: To be a leader in public pharmaceutical and healthcare industry, setting quality and ethical standards and driving high‑quality development across the sector.
• Core emphasis: Integration of TCM heritage with modern drug development and advanced delivery systems to serve family health needs across all ages.

Mission-driven priorities and measurable commitments

• Customer focus: product portfolios and channel strategies designed to address diverse consumer needs across chronic care, acute treatments, and daily health maintenance.
• Innovation: sustained R&D investments to advance new formulations, biologics and delivery technologies, with R&D intensity maintained as a strategic KPI.
• Sustainability & social responsibility: engagement in environmental protection initiatives, community health programs and public‑health education campaigns.
• Industry leadership: active role in standard-setting, quality assurance and cross-sector collaborations to raise public pharmaceutical standards.

How the mission translates into operations

• Product strategy: broad portfolio spanning TCM classics, modernized TCM formulations, OTC consumer health products and select prescription drugs to cover multi‑generational needs.
• R&D approach: platform-based research combining TCM ingredient validation, formulation science and novel delivery (e.g., sustained‑release, transdermal) to improve adherence and outcomes.
• Sustainability measures: investments in cleaner production, waste reduction in manufacturing, and community health outreach programs targeted at underserved regions.
• Quality & compliance: robust GMP-aligned manufacturing footprint and regulatory affairs capability to meet domestic and export standards.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ) - Mission Statement

• Deliver high-quality pharmaceutical and healthcare products that meet the needs of every family member, spanning TCM, OTC, prescription, and consumer health categories.
• Promote the inheritance, modernization and industrialization of traditional Chinese medicine by combining classical formulations with contemporary R&D and manufacturing standards.
• Drive high-quality development as a publicly listed leader through corporate governance, compliance, transparency and investor-focused performance.
• Expand domestic and international market reach via strategic partnerships, M&A, and co-development with global pharma firms.
• Embed sustainability into operations-reducing environmental footprint, improving resource efficiency, and engaging in community health initiatives.

• Integrate traditional Chinese medicine with modern pharmaceutical practices to innovate new products and delivery formats that meet contemporary safety and efficacy standards.
• Scale global presence through selective alliances and co-development agreements with international pharmaceutical companies to access new markets and advanced technologies.
• Position sustainability and social responsibility at the core of corporate strategy-participating in environmental protection initiatives, public health campaigns, and programs to improve access to essential medicines.
• Be recognized as an industry benchmark for quality, compliance and patient-centric product design.

• Environmental initiatives: investments in cleaner production, waste reduction and energy efficiency upgrades across key manufacturing sites to lower emissions and water usage per unit of output.
• Community health: nationwide health education campaigns, free clinics and donation programs aimed at improving chronic disease management and elderly care accessibility.
• Compliance & governance: continuous strengthening of quality systems (GMP), pharmacovigilance, and investor disclosure practices to align with public-company standards.

• Targeted co-development: strategic alliances with global pharmaceutical firms to jointly develop TCM-derived therapeutics, modernized formulations and new OTC products.
• Market entry strategy: prioritize regions with high demand for TCM and consumer healthcare-Southeast Asia, Greater China markets outside mainland, and selected Western markets via licensing and joint ventures.
• Cross-border R&D collaborations: leverage international clinical networks and regulatory expertise to accelerate product approvals and global market access.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ) - Vision Statement

• Integrity: Uphold the highest standards of transparency and ethical conduct across manufacturing, distribution, clinical cooperation, and corporate governance.
• Performance: Deliver consistent quality and operational excellence-driving product reliability, regulatory compliance, and customer satisfaction.
• People: Invest in talent development, workplace safety, and a collaborative culture that empowers employees and clinical partners.
• Partnership: Build long-term, trust-based relationships with hospitals, wholesalers, suppliers, regulators, and research institutions.
• Innovation: Prioritize R&D and pipeline development to introduce differentiated medicines and improve therapeutic outcomes.
• Sustainability: Integrate environmental protection, social responsibility, and governance practices into strategic decision-making.

• Patient-centric product portfolio expansion-focus on anti-infectives, cardiovascular metabolic therapies, and emerging specialty segments.
• Scaled R&D investment to enhance in-house discovery and accelerate clinical development through external collaborations.
• Operational excellence programs targeting supply-chain resilience, GMP upgrades, and digital quality controls.
• Sustainability programs emphasizing emissions reduction, waste management in production, and community health initiatives.

• Integrity: Annual compliance training for 100% of employees and third-party supplier audits across critical sites.
• Performance: Continuous improvement initiatives targeting a 5-8% YoY increase in manufacturing throughput and reduced OTC-to-prescription lead times.
• People: Talent programs and leadership development; internal promotion rates prioritized in annual HR planning.
• Partnership: Strategic alliances with domestic hospitals and CMOs to broaden clinical access and scale production capacity.
• Innovation: Pipeline acceleration through in‑licensing and internal projects supported by >RMB 1bn annual R&D spend.
• Sustainability: Investments in effluent treatment and energy efficiency projects to lower environmental footprint per unit produced.